Sichuan Biokin Pharmaceutical (SHA:688506) received approval from China's National Medical Products Administration for the clinical trials of combination therapies with the drug, BL-M14D1 (DLL3ADC), according to a Shanghai bourse filing on Monday.
The regulator allows the drug to be tested with PD-L1 monoclonal antibodies, anti-angiogenic agents and chemotherapy for the treatment of small cell lung cancer.
The drugmaker's shares rose 2% during the morning trade Monday.
Asia Commercial (HKG:0104) expects a net profit of at least HK$39 million for the year ended March 31, up from HK$24 million a year prior, according to a Friday Hong Kong bourse filing.The watch seller attributed the forecast to a reduction in fair value losses on investment properties.
Central Plains Environment Protection (SHE:000544) wholly-owned subsidiary Zhengzhou Xinhong Reclaimed Water Resources Development and Utilization will invest 10 million yuan to establish a clean energy supply company.The newly-established company will utilize local reclaimed water, geothermal, and other resources, according to a Friday filing with the Shenzhen bourse.
OKG Technology (HKG:1499) expects an attributable loss of at least HK$20 million for the year ended March 31, compared with HK$15.8 million a year prior, according to a Friday Hong Kong bourse filing.The construction engineering company attributed the forecast to a lower revenue from the foundation, building construction work, and ancillary services segment.